Skip to content

    CytomX Therapeutics (CTMX) stock price & financials

    View CTMX earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance+55.1% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $33.43M
    $38.09M
    $50.92M
    $18.66M
    $5.96M
    -82.2%
    $663.0K
    -98.3%
    $10.26M
    -79.9%
    $1.42M
    -92.4%
    Weakening
    Operating Profit
    $4.11M
    $17.68M
    $22.62M
    -$1.29M
    -$15.77M
    -483.6%
    -$27.93M
    -258.0%
    -$19.67M
    -187.0%
    -$23.78M
    -1749.2%
    Weakening
    Net Profit
    $5.74M
    $18.88M
    $23.52M
    -$154.0K
    -$14.23M
    -348.1%
    -$26.51M
    -240.4%
    -$18.25M
    -177.6%
    -$20.67M
    -13319.5%
    Weakening
    EPS
    Other Income
    Interest
    Depreciation
    Profit before Tax
    $5.80M
    $18.94M
    $23.59M
    -$91.0K
    -$14.17M
    -344.5%
    -$26.45M
    -239.7%
    -$18.19M
    -177.1%
    -$20.61M
    -22544.0%
    Weakening
    MarginsOPM
    12.3%
    46.4%
    44.4%
    -6.9%
    -264.4%
    -2249.8%
    -4212.8%
    -9177.4%
    -191.8%
    -531.6%
    -1677.1%
    -24240.8%
    Weakening
    Tax
    1.1%
    0.3%
    0.3%
    -69.2%
    -0.4%
    -139.0%
    -0.2%
    -163.6%
    -0.3%
    -223.1%
    -0.3%
    +99.6%
    Weakening
    ReturnsROIC
    -0.8%
    -2.5%
    -3.1%
    0.0%
    1.9%
    3.5%
    2.4%
    2.8%
    +13319.5%
    Strengthening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$247.58M$188.43M$191.86M$205.53M$193.65M$17.17M$38.05M$12.67M$17.22M
    Short-Term Investments
    Total Current Assets$445.48M$303.33M$324.01M$310.30M$237.10M$182.94M$107.31M$143.92M$373.15M
    Net PP&E$6.93M$32.75M$29.45M$25.32M$21.02M$16.18M$10.60M$4.70M$6.12M
    Goodwill$949.0K$949.0K$949.0K$949.0K$949.0K$949.0K$949.0K$949.0K$949.0K
    Intangibles
    Total Assets$457.11M$341.28M$358.66M$339.41M$260.89M$201.79M$120.53M$151.57M$381.23M
    LiabilitiesTotal Current Liabilities$97.91M$85.59M$68.11M$77.87M$152.61M$155.91M$85.77M$46.62M$39.86M
    Short-Term Debt
    Long-Term Debt
    Long-Term Leases$24.87M$21.68M$18.06M$13.97M$9.38M$4.24M$0$4.21M
    Total Liabilities$326.23M$290.17M$366.44M$339.87M$346.64M$249.24M$120.99M$52.56M$79.16M
    EquityCommon Stock & APIC$1.0K$1.0K$1.0K$1.0K$1.0K$1.0K$1.0K$2.0K$2.0K
    Retained Earnings-$314.98M-$442.87M-$507.69M-$623.56M-$722.88M-$723.45M-$691.58M-$711.95M-$750.86M
    Total Equity$135.83M$25.47M-$7.77M-$459.0K-$85.75M-$47.45M-$456.0K$99.01M$302.07M
    HighlightsNet Cash / (Debt)

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating-$75.52M-$140.48M$5.26M-$119.03M-$110.79M-$56.03M-$86.23M-$75.59M-$82.41M
    Cash from Investing$5.93M$79.70M-$18.72M$22.49M$98.26M-$150.67M$99.70M-$59.74M-$200.80M
    Cash from Financing$139.62M$1.63M$16.89M$110.21M$648.0K$30.23M$7.52M$110.45M$251.89M
    SummaryCapital Expenditure-$3.79M-$3.50M-$2.31M-$1.61M-$1.74M-$840.0K-$310.0K-$220.0K-$74.0K
    Free Cash Flow-$79.31M-$143.98M$2.95M-$120.64M-$112.53M-$56.88M-$86.54M-$75.81M-$82.48M
    FCF Margin-133.3%-535.2%4.3%-323.3%-211.7%-56.2%-62.7%-99.5%-450.7%

    Ratios